WO2002004019A3 - Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen - Google Patents

Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen Download PDF

Info

Publication number
WO2002004019A3
WO2002004019A3 PCT/EP2001/007978 EP0107978W WO0204019A3 WO 2002004019 A3 WO2002004019 A3 WO 2002004019A3 EP 0107978 W EP0107978 W EP 0107978W WO 0204019 A3 WO0204019 A3 WO 0204019A3
Authority
WO
WIPO (PCT)
Prior art keywords
strains
liver
organ fibrosis
virus against
against organ
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/007978
Other languages
English (en)
French (fr)
Other versions
WO2002004019A2 (de
Inventor
Claudia Hirth-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Olaf Weber
Gudrun Theiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122233A external-priority patent/DE10122233A1/de
Priority to IL15382601A priority Critical patent/IL153826A0/xx
Priority to HU0303830A priority patent/HU227668B1/hu
Priority to CN018151272A priority patent/CN1452496B/zh
Priority to LU90996A priority patent/LU90996B1/en
Priority to CA2415399A priority patent/CA2415399C/en
Priority to FI20030038A priority patent/FI20030038A7/fi
Priority to KR1020037000310A priority patent/KR100845643B1/ko
Priority to EP01965110A priority patent/EP1303302B1/de
Priority to MXPA03000278A priority patent/MXPA03000278A/es
Priority to HR20030097A priority patent/HRP20030097A2/xx
Priority to JP2002508473A priority patent/JP5106736B2/ja
Priority to NZ52353501A priority patent/NZ523535A/xx
Priority to DK01965110.8T priority patent/DK1303302T3/da
Priority to HK03106614.0A priority patent/HK1054330B/zh
Priority to GB0302629A priority patent/GB2383752B/en
Application filed by Bayer AG filed Critical Bayer AG
Priority to AU8582701A priority patent/AU8582701A/xx
Priority to SI200120047A priority patent/SI21171A/sl
Priority to AU2001285827A priority patent/AU2001285827B2/en
Priority to AT01965110T priority patent/ATE445413T1/de
Priority to DE50115181T priority patent/DE50115181D1/de
Priority to EEP200300019A priority patent/EE200300019A/xx
Priority to PL36083901A priority patent/PL360839A1/xx
Priority to SK38-2003A priority patent/SK382003A3/sk
Priority to BRPI0112411-0 priority patent/BRPI0112411B8/pt
Publication of WO2002004019A2 publication Critical patent/WO2002004019A2/de
Publication of WO2002004019A3 publication Critical patent/WO2002004019A3/de
Priority to NO20030081A priority patent/NO20030081D0/no
Priority to BG107447A priority patent/BG107447A/bg
Priority to DK200300014A priority patent/DK200300014A/da
Priority to SE0300033A priority patent/SE0300033L/xx
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Die vorliegende Erfindung betrifft die Humanverwendung von inaktivierten Parapoxviren bei der Prophylaxe und Behandlung von Erkrankungen, die mit erhöhter Kollagenablagerung einhergehen, wobei sowohl innere Organe, wie z.B. die Leber, als auch die Haut und ihre Anhangsgebilde betroffen sein können. Insbesondere sind betroffen Leberfibrose bzw. Leberzirrhose im Gefolge von Virushepatitis oder Ethanol-induzierten Lebererkrankungen sowie Zystische Fibrose.
PCT/EP2001/007978 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen Ceased WO2002004019A2 (de)

Priority Applications (28)

Application Number Priority Date Filing Date Title
BRPI0112411-0 BRPI0112411B8 (pt) 2000-07-11 2001-07-11 uso de isolados de vírus parapox inativado
AU8582701A AU8582701A (en) 2000-07-11 2001-07-11 Use of strains of the parapox ovis virus against organ fibrosis
CN018151272A CN1452496B (zh) 2000-07-11 2001-07-11 绵羊副痘病毒毒株抗器官纤维化的用途
LU90996A LU90996B1 (en) 2000-07-11 2001-07-11 Use of the strains of the parapox ovis virus against fibrosis
CA2415399A CA2415399C (en) 2000-07-11 2001-07-11 Use of strains of the parapox ovis virus against organ fibrosis
FI20030038A FI20030038A7 (fi) 2000-07-11 2001-07-11 Parapoxvirus ovis-kantojen käyttö elinfibrooseja vastaan
KR1020037000310A KR100845643B1 (ko) 2000-07-11 2001-07-11 기관 섬유증에 대한 파라폭스바이러스 오비스 균주의 용도
EP01965110A EP1303302B1 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen
MXPA03000278A MXPA03000278A (es) 2000-07-11 2001-07-11 Uso de cepas de parapoxvirus ovis frente a fibrosis de organos.
HR20030097A HRP20030097A2 (en) 2000-07-11 2001-07-11 Use of strains of the parapox ovis virus against organ fibrosis
JP2002508473A JP5106736B2 (ja) 2000-07-11 2001-07-11 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用
NZ52353501A NZ523535A (en) 2000-07-11 2001-07-11 Use of strains of the Parapoxvirus ovis against organ fibroses
DK01965110.8T DK1303302T3 (da) 2000-07-11 2001-07-11 Anvendelse af stammer af parapox ovis virus mod organfibroser
HK03106614.0A HK1054330B (zh) 2000-07-11 2001-07-11 綿羊副痘病毒毒株抗器官纖維化的用途
GB0302629A GB2383752B (en) 2000-07-11 2001-07-11 Use of strains of the parapox ovis virus against organ fibrosis
IL15382601A IL153826A0 (en) 2000-07-11 2001-07-11 Use of strains of the parapox ovis virus against organ fibrosis
AU2001285827A AU2001285827B2 (en) 2000-07-11 2001-07-11 Use of strains of the parapox ovis virus against organ fibrosis
HU0303830A HU227668B1 (en) 2000-07-11 2001-07-11 Use of strains of the parapox ovis virus against organ fibrosis
SI200120047A SI21171A (sl) 2000-07-11 2001-07-11 Uporaba sevov parapoksvirusa ovis proti fibrozi organov
AT01965110T ATE445413T1 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen
DE50115181T DE50115181D1 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen
EEP200300019A EE200300019A (et) 2000-07-11 2001-07-11 Parapoxvirus ovis tüvede kasutamine organite fibrooside vastu
PL36083901A PL360839A1 (pl) 2000-07-11 2001-07-11 Zastosowanie szczepów owczych parapoksywirusów przeciw zwłóknieniu narządów
SK38-2003A SK382003A3 (en) 2000-07-11 2001-07-11 Use of strains of the Parapox ovis virus against organ fibrosis
BG107447A BG107447A (bg) 2000-07-11 2003-01-08 Приложение на щамове parapoxvirus ovis при органни фибрози
NO20030081A NO20030081D0 (no) 2000-07-11 2003-01-08 Anvendelse av stammer fra parapoxvirus mot organfibroser
DK200300014A DK200300014A (da) 2000-07-11 2003-01-10 Anvendelse af stammer af Parapoxvirus ovis mod organfibroser
SE0300033A SE0300033L (sv) 2000-07-11 2003-01-10 Användning av stammar av Parapoxviruset ovis mot organfibroser

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10033581.0 2000-07-11
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
DE10122233.5 2001-05-08

Publications (2)

Publication Number Publication Date
WO2002004019A2 WO2002004019A2 (de) 2002-01-17
WO2002004019A3 true WO2002004019A3 (de) 2002-08-01

Family

ID=26006334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/007978 Ceased WO2002004019A2 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen

Country Status (30)

Country Link
US (1) US6632647B2 (de)
EP (1) EP1303302B1 (de)
JP (1) JP5106736B2 (de)
CN (1) CN1452496B (de)
AR (1) AR028800A1 (de)
AU (2) AU2001285827B2 (de)
BG (1) BG107447A (de)
CA (1) CA2415399C (de)
CZ (1) CZ200372A3 (de)
DK (1) DK200300014A (de)
EE (1) EE200300019A (de)
FI (1) FI20030038A7 (de)
GB (1) GB2383752B (de)
HK (1) HK1054330B (de)
HR (1) HRP20030097A2 (de)
HU (1) HU227668B1 (de)
IL (1) IL153826A0 (de)
LT (1) LT5064B (de)
LU (1) LU90996B1 (de)
LV (1) LV12991B (de)
MA (1) MA25765A1 (de)
MX (1) MXPA03000278A (de)
NO (1) NO20030081D0 (de)
NZ (1) NZ523535A (de)
PL (1) PL360839A1 (de)
RU (1) RU2003104522A (de)
SE (1) SE0300033L (de)
SI (1) SI21171A (de)
SK (1) SK382003A3 (de)
WO (1) WO2002004019A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
AU2002362072A1 (en) 2001-12-07 2003-06-23 Board Of Regents The University Of Texas System Use a parapox b2l protein to modify immune responses to administered antigens
US6752995B2 (en) 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
EP1574211A1 (de) * 2004-03-09 2005-09-14 Inserm Verwendung von CB1-Rezeptor-Antagonisten zur Herstellung eines Arzneimittels zur Behandlung von Lebererkrankungen
WO2012045473A1 (en) * 2010-10-07 2012-04-12 Technische Universität München Viruses for the treatment of fibrosis
CA3018307A1 (en) 2016-02-16 2017-08-24 Osaka University Pharmaceutical composition for use in treating fibrosis
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022978A1 (en) * 1994-02-23 1995-08-31 Anton Mayr Paramunity inducer based on combinations of poxvirus components, process to prepare it and its use as medicament
WO1997038724A1 (de) * 1996-04-15 1997-10-23 Anton Mayr Neue indikationen für die verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren als arzneimittel
WO2000069455A2 (de) * 1999-05-14 2000-11-23 Bayer Aktiengesellschaft Organ-, gewebs- und zellspezifisches immuntherapeutikum für chronische virale infektionen, sowie entzündliche, degenerative und proliferative erkrankungen insbesondere der leber sowie krebs auf der basis von rekombinantem parapoxvirus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4360510A (en) * 1979-11-30 1982-11-23 Proctor Julian W Method for screening anti-tumor agents of the reticulo-endothelial stimulant class
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
DE3504940C2 (de) 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
DE3816139A1 (de) * 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
IL139593A (en) * 2000-11-09 2010-12-30 Biogem Optical Ltd Method for the detection of viable microorganisms

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022978A1 (en) * 1994-02-23 1995-08-31 Anton Mayr Paramunity inducer based on combinations of poxvirus components, process to prepare it and its use as medicament
WO1997038724A1 (de) * 1996-04-15 1997-10-23 Anton Mayr Neue indikationen für die verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren als arzneimittel
WO2000069455A2 (de) * 1999-05-14 2000-11-23 Bayer Aktiengesellschaft Organ-, gewebs- und zellspezifisches immuntherapeutikum für chronische virale infektionen, sowie entzündliche, degenerative und proliferative erkrankungen insbesondere der leber sowie krebs auf der basis von rekombinantem parapoxvirus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FRIEDMAN SCOTT L.: "Evaluation of fibrosis and hepatitis C", THE AMERICAN JOURNAL OF MEDICINE, vol. 107, no. 6B, 1999, pages 27s - 30s, XP001022493 *

Also Published As

Publication number Publication date
SE0300033L (sv) 2003-03-10
JP2004502741A (ja) 2004-01-29
US6632647B2 (en) 2003-10-14
HRP20030097A2 (en) 2005-02-28
CN1452496B (zh) 2012-10-10
LT2003008A (en) 2003-07-25
DK200300014A (da) 2003-03-07
HUP0303830A3 (en) 2004-10-28
HK1054330B (zh) 2005-07-15
HK1054330A1 (en) 2003-11-28
NO20030081L (no) 2003-01-08
EP1303302A2 (de) 2003-04-23
IL153826A0 (en) 2003-07-31
NO20030081D0 (no) 2003-01-08
AU8582701A (en) 2002-01-21
SE0300033D0 (sv) 2003-01-10
SI21171A (sl) 2003-10-31
RU2003104522A (ru) 2004-06-27
CN1452496A (zh) 2003-10-29
MXPA03000278A (es) 2004-04-05
LT5064B (lt) 2003-11-25
US20020076418A1 (en) 2002-06-20
NZ523535A (en) 2004-12-24
EE200300019A (et) 2004-10-15
LV12991B (en) 2003-08-20
WO2002004019A2 (de) 2002-01-17
HU227668B1 (en) 2011-11-28
CA2415399C (en) 2011-11-08
GB0302629D0 (en) 2003-03-12
LU90996B1 (en) 2003-01-08
AR028800A1 (es) 2003-05-21
GB2383752A (en) 2003-07-09
HUP0303830A2 (hu) 2004-04-28
CA2415399A1 (en) 2003-01-08
MA25765A1 (fr) 2003-04-01
SK382003A3 (en) 2003-07-01
PL360839A1 (pl) 2004-09-20
AU2001285827B2 (en) 2006-11-30
BG107447A (bg) 2003-09-30
GB2383752B (en) 2004-11-24
CZ200372A3 (cs) 2003-05-14
JP5106736B2 (ja) 2012-12-26
FI20030038A7 (fi) 2003-03-10
EP1303302B1 (de) 2009-10-14

Similar Documents

Publication Publication Date Title
WO2007076034A3 (en) Anti-viral compounds
WO2007081517A3 (en) Anti-viral compounds
WO2007076035A3 (en) Anti-viral compounds
WO2003055896A3 (en) Anti-viral 7-deaza l-nucleosides
CA2413163A1 (en) 3'-prodrugs of 2'-deoxy-.beta.-l-nucleosides
WO2001077091A3 (en) Ns5b hcv polymerase inhibitors
WO2008133753A3 (en) Anti-viral compounds
WO2001010456A3 (en) Peptides that block viral infectivity and methods of use thereof
EP2284268A3 (de) Konservierte HBV- und HCV-Sequenzen zur Genausschaltung
EP1256348A4 (de) Heilmittel gegen hepatitis
WO2002004019A3 (de) Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen
WO2002062959A3 (en) Hepatitis b virus treatment
HK1054329A1 (en) Use of strains of parapoxvirus ovis for producing antiviral medicaments and medicaments against cancer
WO2005063281A3 (de) Mittel zur hemmung der virusreplikation durch regulation der proteinfaltung
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
WO2002044334A3 (en) Recombinant rsv virus expression systems and vaccines
WO2001097824A3 (de) Verwendung von phyllanthusbestandteilen zur behandlung oder prophylaxe von infekten durch flaviviridae
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
WO2003006654A3 (en) Recombinant proteins of parapoxvirus ovis and pharmaceutical compositions therefrom
WO2000069455A3 (de) Organ-, gewebs- und zellspezifisches immuntherapeutikum für chronische virale infektionen, sowie entzündliche, degenerative und proliferative erkrankungen insbesondere der leber sowie krebs auf der basis von rekombinantem parapoxvirus
AU2001285827A1 (en) Use of strains of the parapox ovis virus against organ fibrosis
AU2001285827A2 (en) Use of strains of the parapox ovis virus against organ fibrosis
WO2002046214A3 (en) Immunomodulatory protein derived from the yaba monkey tumor virus
TH64257A (th) การใช้สายพันธุ์ของ Parapoxvirus Ovis ในการต่อต้านโรคไฟโบรซิสของอวัยวะ
WO2000015210A3 (en) Use of mycophenol acid and its derivatives for the treatment of virus diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 0302629

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20010711

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001965110

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/01885/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 153826

Country of ref document: IL

Ref document number: 2001285827

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 523535

Country of ref document: NZ

Ref document number: 2415399

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/000278

Country of ref document: MX

Ref document number: PV2003-72

Country of ref document: CZ

Ref document number: 1020037000310

Country of ref document: KR

Ref document number: 03001020

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2003 200300019

Country of ref document: RO

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2003/00276

Country of ref document: ZA

Ref document number: 382003

Country of ref document: SK

Ref document number: 091532001

Country of ref document: AT

Ref document number: 200300276

Country of ref document: ZA

Ref document number: 20030038

Country of ref document: FI

ENP Entry into the national phase

Ref document number: 200350003

Country of ref document: ES

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P200350003

Country of ref document: ES

WWE Wipo information: entry into national phase

Ref document number: A9153/2001

Country of ref document: AT

WWE Wipo information: entry into national phase

Ref document number: 2003008

Country of ref document: LT

WWE Wipo information: entry into national phase

Ref document number: 200120047

Country of ref document: SI

WWE Wipo information: entry into national phase

Ref document number: P20030097A

Country of ref document: HR

ENP Entry into the national phase

Ref document number: 2003104522

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWE Wipo information: entry into national phase

Ref document number: 018151272

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020037000310

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001965110

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-72

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2003117427

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2003117713

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2003008

Country of ref document: LT

WWG Wipo information: grant in national office

Ref document number: 2003008

Country of ref document: LT

WWP Wipo information: published in national office

Ref document number: 523535

Country of ref document: NZ

REG Reference to national code

Ref country code: PT

Ref legal event code: FG4A

Effective date: 20010711

WWG Wipo information: grant in national office

Ref document number: 523535

Country of ref document: NZ

REG Reference to national code

Ref country code: PT

Ref legal event code: FG4A

Effective date: 20010123

WWR Wipo information: refused in national office

Ref document number: 200350003

Country of ref document: ES

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 2001285827

Country of ref document: AU